If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 181 - 190 of 275
NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa
Objective
Oral N-acetylcysteine for Retinitis Pigmentosa -NAC Attack
Protocol No
OPH-NEI-NAC-ATTACK
Categories
Transgender Care Research Study
Objective
Transgender Ensemble Project
Protocol No
PLS-IIT-DOREN-TRANS-ENSEMBLE
Categories
Metaboreflex in Stroke Survivors
Objective
Metaboreflex in Stroke Survivors
Protocol No
PMR-IIT-DURAND-METABOREFLEX
Blood Flow Regulation and Neuromuscular Function Post-Stroke
Objective
Blood Flow Post Stroke
Protocol No
PMR-IIT-DURANT-BLOOD-FLOW
A Prospective, Multicountry Study To Estimate The Incidence Of And Provide A Best Practice Model For Monitoring The Development Of Post-Stroke Spasticity
Objective
Best Practice Model For Monitoring The Development Of Post-Stroke Spasticity
Protocol No
PMR-IPSEN-EPITOME
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera system in Subjects with Upper Extremity Spasticity
Objective
Iovera in Upper Extremity Spasticity
Protocol No
PMR-PACIRA-IOV-301
A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
Objective
Lower Respiratory Tract PIV Infection in Immunocompromised Subjects
Protocol No
PULM-ANSUN-BIOPHARMA-FQ
Categories
Reparixin 1200 mg TID as add-on to SoC to Limit Disease Progression in Hospitalised Patients With COVID-19 and Other Community-Acquired Pneumonia. A Multicentre, Randomised, Double-blinded, Placebo-controlled, Phase III Trial (REPAVID-22)
Objective
Reparixin as add-on to SOC to Limit Disease Progression in COVID-19 and Pneumonia
Protocol No
PULM-DOMPE-REPAVID-22
Categories
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)
Objective
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Protocol No
PULM-GOSSAMER-PROSERA
Categories
A Randomized Controlled Trial of an iPad for Patient Communication during Mechanical Ventilation
Objective
iPad for Patient Communication
Protocol No
PULM-IPAD
Categories